graphic
News > Companies
Bayer picks new CEO
September 14, 2001: 3:46 p.m. ET

But German firm's woes deepen as it embraces go-it-alone stance
graphic
graphic graphic
graphic
NEW YORK (CNNfn) - The month-long swoon in Bayer AG's share price gathered pace Friday as the market accepted that not even the loss of its most promising drug would make the company change its pharmaceuticals strategy.

Bayer said Thursday its chief financial officer, Werner Wenning, will become chief executive in April and moved to dampen speculation it will sell its drug business despite the fallout in the past month over the costly withdrawal of its Baycol anti-cholesterol treatment.

  graphic
German chemical maker Bayer AG picks Werner Wenning (above) to succeed its current CEO, Manfred Schneider.
The news dashed hopes that Bayer, stricken after Baycol was linked with 52 deaths around the world, would agree to a joint venture in which it had minority control.

Such a venture would give the Leverkusen, Germany-based company's pharmaceutical unit the critical mass it needs to compete with its 15 or so larger rivals around the world.

Wenning succeeds Manfred Schneider, whose departure was long expected.

Shares of Bayer have lost a third of their value since Aug. 8, including a 4.66 percent drop Friday after a 3 percent drop Thursday.

Hope and disappointment

The disappointment was underscored by a flurry of downgrades Friday, with UBS Warburg lowering its price target to graphic35 from graphic41 and Bankgesellschaft cutting Bayer to "hold" from "accumulate."

Lehman Brothers reduced its Bayer rating to "market perform" from "buy."

"We are very disappointed by Bayer's hasty decision to retain pharma as a core business," Lehman analyst Jennifer Barker said in a research note.

"The hastiness of the decision suggests that the management has not been fully objective. Bayer's senior management, including the new CEO-designate, Werner Wenning, many have let their hearts rule their heads," she said.

Bayer argues its "four pillar" strategy combining chemicals, drugs, agrochemicals and polymers reaps synergies, but it also is seen as loath to sell the pharmaceutical operations, which invented aspirin a century ago.

Wenning, 54, has been a Bayer employee since 1966 and management board member since 1997. He is thought more open to change than Schneider, who has been head of the board since 1992 and resisted calls for a breakup.

The drug business had sales of graphic6.1 billion last year. The firm's health-care operations, which include consumer care and diagnostics, had sales of graphic10 billion.

Bristol-Myers (BMY: Research, Estimates) and Eli Lilly (LLY: Research, Estimates), Franco-German Aventis and Switzerland's Roche and Novartis all have been named by analysts as possible partners for Bayer's drug unit.

Bankers have played down a newspaper report that Britain's GlaxoSmithKline was poised to bid up to $15 billion for the drug unit, while Roche has denied holding talks with Bayer about buying it.

-- from staff and wire reports graphic

  RELATED STORIES

Drugs and chemicals maker faces negligence investigation in Germany - Sept. 4, 2001

Bayer ends sale of cholesterol drug Baycol in Japan - Aug. 23, 2001

  RELATED SITES

CNNfn: TIPS FROM THE TOP

Bayer Group


Note: Pages will open in a new browser window
External sites are not endorsed by CNNmoney




graphic


Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.